State of Wyoming Reduces Stock Position in DexCom, Inc. $DXCM

Posted by Brian Himes on Aug 1st, 2026

State of Wyoming cut its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 69.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 2,930 shares of the medical device company’s stock after selling 6,578 shares during the period. State of Wyoming’s holdings in DexCom were worth $184,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Reflection Asset Management bought a new position in shares of DexCom in the 4th quarter valued at about $25,000. Ascentis Independent Advisors bought a new stake in DexCom during the first quarter worth approximately $25,000. MCF Advisors LLC bought a new stake in DexCom during the fourth quarter worth approximately $32,000. DV Equities LLC purchased a new stake in DexCom during the fourth quarter valued at approximately $36,000. Finally, Spire Wealth Management raised its position in DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 305 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Key DexCom News

Here are the key news stories impacting DexCom this week:

Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

DexCom Stock Up 12.0%

Shares of NASDAQ DXCM opened at $83.45 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The company has a market cap of $32.20 billion, a P/E ratio of 32.98, a PEG ratio of 1.23 and a beta of 1.45. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $87.00. The firm has a 50-day simple moving average of $73.14 and a two-hundred day simple moving average of $69.20.

DexCom (NASDAQ:DXCM – Get Free Report) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.34% and a net margin of 20.12%.The company’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.48 earnings per share. Research analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DXCM shares. Bank of America lowered their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Sanford C. Bernstein set a $77.00 price target on DexCom in a report on Friday, May 1st. Piper Sandler restated an “overweight” rating and set a $95.00 price target (up from $88.00) on shares of DexCom in a report on Friday. UBS Group set a $96.00 price target on DexCom and gave the stock a “buy” rating in a research report on Tuesday. Finally, Citigroup reaffirmed a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $88.12.

Read Our Latest Stock Report on DexCom

Insider Activity

In related news, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider owned 328,970 shares in the company, valued at $25,106,990.40. The trade was a 7.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,506 shares of company stock worth $7,205,258 in the last three months. Corporate insiders own 0.28% of the company’s stock.

DexCom Company Profile

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.